US 12,447,211 B2
Therapeutic derivatives of interleukin-22
Kristian Sass-Ørum, Bagsværd (DK); Rasmus Jørgensen, Hellerup (DK); Sebastian Beck Jørgensen, Bagsvaerd (DK); Henning Thøgersen, Bagsværd (DK); Thomas Hoeg-Jensen, Bagsværd (DK); and Michael Paolo Bastner Sandrini, Bagsværd (DK)
Assigned to CytoKi Pharma ApS, Hellerup (DK)
Filed by CytoKi Pharma ApS, Hellerup (DK)
Filed on Jun. 30, 2023, as Appl. No. 18/345,832.
Application 18/345,832 is a continuation of application No. 17/737,849, filed on May 5, 2022, granted, now 11,806,403.
Application 17/737,849 is a continuation of application No. PCT/EP2020/081523, filed on Nov. 9, 2020.
Claims priority of application No. 19207766 (EP), filed on Nov. 7, 2019.
Prior Publication US 2024/0108731 A1, Apr. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/54 (2017.01); A61P 1/16 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); A61P 11/00 (2006.01)
CPC A61K 47/542 (2017.08) [A61P 1/16 (2018.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); A61P 11/00 (2018.01)] 15 Claims
 
1. A derivative of IL-22 comprising a fatty acid covalently attached to an IL-22 protein, wherein
(i) the IL-22 is a variant of native mature human IL-22 (hIL-22; SEQ ID NO. 1), wherein the variant comprises 1, 2, or 3 amino acid substitutions within SEQ ID NO. 1, including an A1C substitution;
(ii) when the variant comprises 2 or 3 amino acid substitutions, the substitutions other than the A1C substitution are:
conservative substitutions; and/or
located at one or more positions selected from positions 21, 35, 64, 113 and 114 of hIL-22; and
(iii) the fatty acid is covalently attached to the substituted Cys residue at position 1.